DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER Virtual Investor Event – December 5, 2020 Forward-Looking Statements | --- | --- | |-------|-------| | | | | | | Today's Agenda Topic Speaker | --- | --- | |------------------------------------------------|----------------------------------------------------------------| | | | | Program overview / KO-539 development timeline | Troy Wilson, Ph.D., J.D. President and Chief Executive Officer | | Introduction of KOMET-001 investigators | Stephen Dale, M ...

DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER Stifel Healthcare Conference – November 16, 2020 Forward-Looking Statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for tipifarnib and KO-539, plans regarding regulatory filings, our expectations regarding the relative benefits of our product candidates versus competitive th ...

Kura Oncology, Inc. (NASDAQ:KURA) Q3 2020 Earnings Conference Call November 5, 2020 8:00 AM ET Company Participants Pete De Spain - Investor Relations Troy Wilson - President and Chief Executive Officer Marc Grasso - Chief Financial Officer Stephen Dale - Chief Medical Officer Jim Basta - Chief Legal Officer Kirsten Flowers - Chief Commercial Officer Kathy Ford - Chief Operating Officer Conference Call Participants Peter Lawson - Barclays Marty Auster - Credit Suisse Ren Benjamin - JMP Securities Alexander ...

DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER Corporate Presentation – August 2020 Forward-Looking Statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for tipifarnib and KO-539, plans regarding regulatory filings, our expectations regarding the relative benefits of our product candidates versus competitive therapies, and ...

DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER Corporate Presentation – May 2020 0 0 Forward-Looking Statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for tipifarnib and KO-539, plans regarding regulatory filings, our expectations regarding the relative benefits of our product candidates versus competitive therapies, an ...